- Chime Biologics has inaugurated its GMP-2 manufacturing facility in Wuhan, China, featuring eight 2,000-liter single-use bioreactors to support biologics development and commercial manufacturing.
- The company also announced plans for an AI-powered Megafactory with more than 100 2,000-liter bioreactors and expects overseas revenue to account for approximately 70% of total revenue within five years.
Chime Biologics has inaugurated its GMP-2 manufacturing facility in Wuhan, China, expanding its biologics manufacturing capacity to support increasing global demand. The new facility is equipped with eight 2,000-liter single-use Xcellerex bioreactors supplied by Cytiva and is designed to provide flexible and scalable manufacturing services for biologics programs from development through commercial production.
The facility builds on a decade-long collaboration between Chime Biologics and Cytiva. According to the companies, Chime Biologics’ first manufacturing site was established using Cytiva’s KUBio modular manufacturing platform, which supported the company’s expansion from early-stage development activities to commercial biologics manufacturing.
The GMP-2 site is intended to support late-stage and commercial manufacturing programs while maintaining manufacturing flexibility and consistent product quality. Chime Biologics said the additional capacity will help meet demand from global biologics customers seeking accelerated commercialization and reliable supply.
“From the world’s first KUBio commercial biosimilars facility in 2016 to today’s GMP-2 launch and future Megafactory vision, Cytiva has been an important strategic partner throughout our growth journey.”
Jimmy Wei, Board Director and CEO of Chime Biologics
In addition to the GMP-2 launch, Chime Biologics announced plans to invest in an AI-powered Megafactory featuring more than 100 2,000-liter bioreactors. The company said the facility is expected to become the largest biologics manufacturing campus in China. Chime Biologics also stated that overseas markets currently account for approximately 50% of its total order value and that it expects revenue from markets outside China to increase to around 70% over the next five years.
